GSK nabs speedy review for one of its top prospects

GSK nabs speedy review for one of its top prospects

Source: 
Fierce Biotech
snippet: 

Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FDA priority review. The speedy appraisal is for its BCMA therapy belantamab mafodotin in relapsed or refractory multiple myeloma, after releasing initial results last summer where it hit its primary goal and demonstrated a “clinically meaningful overall response rate.”